Well that makes me feel better. Its 8:30pm now and I feel like I finally got something right

But there are still so many things that I don't understand.

CD12's DSMC suggested no changes to a clinical trial for which they knew for certain the power would fail. Surely CYDY knows the power will fail as well.

The DSMC observed placebo deaths between day 28 and day 42, and asked for an additional 42 day endpoint. But CYDY, despite knowing that the inherent mathematical weaknesses in CD12, did not change the endpoint.

CD10 failed because the trial population was defective. Should have been moderate only. Sanofi/Roche says placebo mortality for severe is 38%. If true in CD12, LL will get something like 60% mortality reduction, which I certainly believe is not happening. So all that means that CD12 success depends critically on the patient population, which was insufficiently controlled in CD10.

There's more i dont understand but the rest i forgot.

I guess I'll just be happy that I figured out the Landstreet video was six months old.

small victories first, i guess. or at least i hope.